证券代码：601607 证券简称：上海医药 公告编号：临2025-108 上海医药集团股份有限公司 关于召开2025年第二次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海医药集团股份有限公司（以下简称"上海医药"、"公司"）于2025 年11月19日在《中国证券报》、《上海证券报》、《证券日报》、《证券时报》 和上海证券交易所网站（www.sse.com.cn）上刊登了《上海医药集团股份有限 公司关于召开2025年第二次临时股东大会的通知》（临2025-107），定于2025 年12月9日以现场投票和网络投票相结合的方式召开2025年第二次临时股东大 会。现将本次会议的有关事项提示如下 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第二次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 1 股东大会召开日期：2025年12月9日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), has received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for its Tramadol Hydrochloride Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Tramadol Hydrochloride Injection is primarily used for the treatment of moderate to severe pain [1]

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its Tramadol Hydrochloride Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Tramadol Hydrochloride Injection is primarily used for the treatment of moderate to severe pain [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Hefeng"), received a Supplementary Application Approval Notice from the National Medical Products Administration for its Tramadol Hydrochloride Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The Tramadol Hydrochloride Injection is primarily used for the treatment of moderate to severe pain [1]

Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its Tramadol Hydrochloride Injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Company Summary - The approved drug is primarily used for the treatment of moderate to severe pain [1]

Group 1 - The A-share market has seen 69 stocks being continuously bought on margin for over 5 days, with 6 stocks experiencing this for 9 consecutive days, indicating a strong interest from investors [1] - The current market environment is likened to a precise gambling game, where traditional strategies like "leading stocks driving others" are failing due to rapid shifts in market hotspots [3] - The phenomenon of stocks being bought on margin reflects a structural layout by major funds rather than short-term speculation, with stocks spread across various sectors such as pharmaceuticals, military, and electricity [9] Group 2 - Successful stocks share two common characteristics: a phenomenon of aggressive buying and the art of shaking off weak hands before a price increase [4][6] - Data from trading systems reveal that stock price movements are not random, as evidenced by stocks that have been continuously bought on margin [9] - The speed of industry rotation is increasing, making human analysis insufficient, while true opportunities are often hidden in data details [10]

Core Insights - As of November 25, a total of 69 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stocks with the longest streak of net financing inflows, at nine consecutive trading days, include Shanghai Pharmaceuticals, Lutai A, Guokai Military Industry, Gongda High-Tech, Shuangle Co., and Huadian International [1] - Other notable stocks with significant net financing inflows include Qibin Group, Zhuoyue Technology, Changyuan Electric Power, Dongcai Technology, Bailong Oriental, Zhongchen Technology, Hongchuan Wisdom, and Tongbao Energy [1]

Core Viewpoint - As of November 21, a total of 91 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Notable Financing Inflows - The stock with the longest consecutive net inflow is Yinlong Co., which has seen net buying for 11 consecutive trading days [1] - Other stocks with significant consecutive net inflows include Huadian International, Jiangsu Shentong, Tubao, Dadi Media, Gaohua Technology, Aide Biology, Aerospace Changfeng, and Shanghai Pharmaceuticals [1]

Market Overview - On November 21, the Shanghai State-Owned Enterprise Reform sector fell by 2.97% compared to the previous trading day, with Tibet City Investment leading the decline [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Shanghai Mechanical and Electrical (600835) saw a closing price of 28.29, with an increase of 4.89% and a trading volume of 427,300 shares, amounting to a transaction value of 1.207 billion [1] - Tibet City Investment (600773) experienced a significant drop of 10.02%, closing at 12.93, with a trading volume of 473,100 shares [2] - Hydrogen Alkali Chemical (600618) and Data Port (603881) also faced declines of 9.53% and 7.83%, respectively [2] Capital Flow - The Shanghai State-Owned Enterprise Reform sector saw a net outflow of 2.59 billion yuan from institutional investors, while retail investors had a net inflow of 2.12 billion yuan [2] - The main capital flow data indicates that Shanghai Mechanical and Electrical had a net inflow of 1.20 billion yuan from institutional investors, while retail investors had a net outflow of 43.99 million yuan [3]

Market Overview - The pharmaceutical commercial sector declined by 1.33% on November 19, with Renmin Tongtai leading the losses [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Jianfa Zhixin rising by 3.19% to a closing price of 34.00, while Renmin Tongtai fell by 9.99% to 15.95 [2][1] - The trading volume for Jianfa Zhixin was 180,800 shares, with a transaction value of 620 million yuan [1] - Other notable stocks included Yifeng Pharmacy, which increased by 0.46%, and Shanghai Pharmaceuticals, which decreased by 0.39% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 436 million yuan from institutional investors, while retail investors saw a net inflow of 408 million yuan [2] - The data indicates that retail investors are more active in the sector despite the overall decline in stock prices [2] Individual Stock Capital Flow - Jianfa Zhixin had a net inflow of 70.39 million yuan from institutional investors, while Renmin Tongtai saw a significant outflow of 1.20 billion yuan from retail investors [3] - Other stocks like Guoyao Yizhi and Zhongyao Holdings also experienced mixed capital flows, with Guoyao Yizhi having a net inflow of 7.36 million yuan from institutional investors [3]